These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 10155350)

  • 1. Cost-effective management of complicated urinary tract infections.
    Cox CE
    Adv Ther; 1995; 12(4):222-35. PubMed ID: 10155350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current challenges in the treatment of complicated urinary tract infections and prostatitis.
    Wagenlehner FM; Naber KG
    Clin Microbiol Infect; 2006 May; 12 Suppl 3():67-80. PubMed ID: 16669930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urologic diseases in America project: trends in resource use for urinary tract infections in women.
    Griebling TL
    J Urol; 2005 Apr; 173(4):1281-7. PubMed ID: 15758783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of urinary tract infections: historical perspective and current strategies: Part 2--Modern management.
    Nickel JC
    J Urol; 2005 Jan; 173(1):27-32. PubMed ID: 15592019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expanding role of fluoroquinolones.
    Schaeffer AJ
    Dis Mon; 2003 Feb; 49(2):129-47. PubMed ID: 12601342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of urinary tract infections among febrile young children with daily intravenous antibiotic therapy at a day treatment center.
    Gauthier M; Chevalier I; Sterescu A; Bergeron S; Brunet S; Taddeo D
    Pediatrics; 2004 Oct; 114(4):e469-76. PubMed ID: 15466073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Community-acquired Pseudomonas aeruginosa urinary tract infections in children hospitalized in a tertiary center: relative frequency, risk factors, antimicrobial resistance and treatment.
    Marcus N; Ashkenazi S; Samra Z; Cohen A; Livni G
    Infection; 2008 Oct; 36(5):421-6. PubMed ID: 18795227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical efficacy of T-3262, a new quinolone compound, on urinary tract infection in 1988].
    Suzuki K; Nagata Y
    Hinyokika Kiyo; 1989 Apr; 35(4):717-26. PubMed ID: 2735274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary tract infection: traditional pharmacologic therapies.
    Nicolle LE
    Dis Mon; 2003 Feb; 49(2):111-28. PubMed ID: 12601341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Urinary tract infections: risk factors and therapeutic trends].
    Margariti PA; Astorri AL; Mastromarino C
    Recenti Prog Med; 1997 Feb; 88(2):65-8. PubMed ID: 9148368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance of uropathogens in symptomatic urinary tract infections in León, Nicaragua.
    Matute AJ; Hak E; Schurink CA; McArthur A; Alonso E; Paniagua M; Van Asbeck E; Roskott AM; Froeling F; Rozenberg-Arska M; Hoepelman IM
    Int J Antimicrob Agents; 2004 May; 23(5):506-9. PubMed ID: 15120732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections.
    Talan DA; Naber KG; Palou J; Elkharrat D
    Int J Antimicrob Agents; 2004 Mar; 23 Suppl 1():S54-66. PubMed ID: 15037329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections.
    Mazzei T; Cassetta MI; Fallani S; Arrigucci S; Novelli A
    Int J Antimicrob Agents; 2006 Aug; 28 Suppl 1():S35-41. PubMed ID: 16829051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
    Arslan H; Azap OK; Ergönül O; Timurkaynak F;
    J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy.
    Wells WG; Woods GL; Jiang Q; Gesser RM
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii67-74. PubMed ID: 15150185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The etiology of urinary tract infection: traditional and emerging pathogens.
    Ronald A
    Dis Mon; 2003 Feb; 49(2):71-82. PubMed ID: 12601338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Etiology of urinary tract infections and antimicrobial susceptibility of urinary pathogens].
    Correia C; Costa E; Peres A; Alves M; Pombo G; Estevinho L
    Acta Med Port; 2007; 20(6):543-50. PubMed ID: 18331698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Types of urethral catheters for management of short-term voiding problems in hospitalized adults: a short version Cochrane review.
    Schumm K; Lam TB
    Neurourol Urodyn; 2008; 27(8):738-46. PubMed ID: 18951451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial agents in urinary tract infections in patients with spinal cord injury.
    Carson CC
    Urol Clin North Am; 1993 Aug; 20(3):443-52. PubMed ID: 8351770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs.
    Foxman B
    Dis Mon; 2003 Feb; 49(2):53-70. PubMed ID: 12601337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.